First-in-Class, First-in-Human Phase 1 Trial of VT3989, an Inhibitor of YAP/TEAD, in Pts With Advanced Solid Tumors Enriched for Malignant Mesothelioma and Other Tumors With NF2 Mutations

61 views
May 4, 2023
Comments 0
Login to view comments. Click here to Login